VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4

Peptides

Volumn 29, Issue 6, 2008, Pages 948-956

  Arranz, Alicia ^a   Juarranz, Yasmina ^a   Leceta, Javier ^a   Gomariz, Rosa P ^a   Martínez, Carmen ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Crohn's disease; LPS; Lymph node; Pam3Cys; TLRs

Indexed keywords

CXCL1 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; PROTEIN P70; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRINITROBENZENESULFONIC ACID; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; CELL CULTURE; COLITIS; CONTROLLED STUDY; DOWN REGULATION; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; MALE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; CELLS, CULTURED; COLITIS; DISEASE MODELS, ANIMAL; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; LYMPH NODES; MALE; MESENTERY; MICE; MICE, INBRED BALB C; MODELS, IMMUNOLOGICAL; TIME FACTORS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TRINITROBENZENESULFONIC ACID; VASOACTIVE INTESTINAL PEPTIDE;

MURINAE;

EID: 43049113127     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2008.01.019     Document Type: Article

References (50)

1. Abad C., Juarranz Y., Martinez C., Arranz A., Rosignoli F., Garcia-Gomez M., et al. cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm Bowel Dis 11 (2005) 674-684
2. Abad C., Martinez C., Juarranz M.G., Arranz A., Leceta J., Delgado M., et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124 (2003) 961-971
3. Akashi S., Shimazu R., Ogata H., Nagai Y., Takeda K., Kimoto M., et al. Cell surface expression and lipopolysaccharide signaling via the Toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol 16 (2000) 3471-3475
4. Arranz A., Abad C., Juarranz Y., Torroba M., Rosignoli F., Leceta J., et al. Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis. Ann N Y Acad Sci 1070 (2006) 129-134
5. Barton G.M., and Medzhitov R. Control of adaptive immune responses by Toll-like receptors. Curr Opin Immunol 14 (2002) 380-383
6. Bustin S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25 (2000) 169-193
7. Caramalho I., Lopes-Carvalho T., Ostler D., Zelenay S., Haury M., and Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 197 (2003) 403-411
8. Delgado M., Abad C., Martinez C., Leceta J., and Gomariz R.P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 7 (2001) 563-568
9. Delgado M., Leceta J., Abad C., Martinez C., Ganea D., and Gomariz R.P. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. J Neuroimmunol 99 (1999) 61-71
10. Delgado M., Martinez C., Pozo D., Calvo J.R., Leceta J., Ganea D., et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol 162 (1999) 1200-1205
11. Foster N., Lea S.R., Preshaw P.M., and Taylor J.J. Pivotal advance: vasoactive intestinal peptide inhibits up-regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages. J Leukoc Biol 81 (2007) 893-903
12. Gomariz R.P., Arranz A., Abad C., Torroba M., Martinez C., Rosignoli F., et al. Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. J Leukoc Biol 78 (2005) 491-502
13. Gomariz R.P., Arranz A., Juarranz Y., Gutierrez-Cañas I., Garcia-Gomez M., Leceta J., et al. Regulation of TLR expression, a new perspective for the role of VIP in immunity. Peptides 28 (2007) 1825-1832
14. Gutiérrez-Cañas I., Juarranz Y., Santiago B., Arranz A., Martinez C., Galindo M., et al. VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. Rheumatology 45 (2006) 527-532
15. Hart O.M., Athie-Morales V., O'Connor G.M., and Gardiner C.M. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol 175 (2005) 1636-1642
16. Hori S., Nomura T., and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003) 1057-1061
17. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 (2004) 987-995
18. Jonuleit H., and Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol 171 (2003) 6323-6327
19. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol 19 (2007) 39-45
20. Kalinski P., Hilkens C.M., Wierenga E.A., and Kapsenberg M.L. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 20 (1999) 561-567
21. Khattri R., Cox T., Yasayko S.A., and Ramsdell F. An essential role for Scurfin in CD4 + CD25 + T regulatory cells. Nat Immunol 4 (2003) 337-342
22. Kobayashi M., Kweon M.N., Kuwata H., Schreiber R.D., Kiyono H., Takeda K., et al. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J Clin Invest 111 (2003) 1297-1308
23. Komai-Koma M., Jones L., Ogg G.S., Xu D., and Liew F.Y. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci USA 101 (2004) 3029-3034
24. Lanzavecchia A., and Sallusto F. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr Opin Immunol 13 (2001) 291-298
25. Lewkowicz P., Lewkowicz N., Sasiak A., and Tchorzewski H. Lipopolysaccharide-activated CD4 + CD25+ T regulatory cells inhibit neutrophil function and promote their apoptosis and death. J Immunol 177 (2006) 7155-7163
26. Lindley S., Dayan C.M., Bishop A., Roep B.O., Peakman M., and Tree T.I. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54 (2005) 92-99
27. Liu H., Hu B., Xu D., and Liew F.Y. CD4 + CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-beta, and CTLA4. J Immunol 171 (2003) 5012-5017
28. Liu H., Komai-Koma M., Xu D., and Liew F.Y. Toll-like receptor 2 signaling modulates the functions of CD4 + CD25+ regulatory T cells. Proc Natl Acad Sci USA 103 (2006) 7048-7053
29. Maloy K.J., and Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2 (2001) 816-822
30. McCormack G., Moriarty D., O'Donoghue D.P., McCormick P.A., Sheahan K., and Baird A.W. Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res 50 (2001) 491-495
31. Medzhitov R., and Janeway Jr. C.A. Decoding the patterns of self and nonself by the innate immune system. Science 296 (2002) 298-300
32. Medzhitov R., Preston-Hurlburt P., and Janeway Jr. C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388 (1997) 394-397
33. Mottet C., Uhlig H.H., and Powrie F. Cutting edge: cure of colitis by CD4 + CD25 + regulatory T cells. J Immunol 170 (2003) 3939-3943
34. Nakamura K., Kitani A., Fuss I., Pedersen A., Harada N., Nawata H., et al. TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 172 (2004) 834-842
35. Neurath M.F., Finotto S., and Glimcher L.H. The role of Th1/Th2 polarization in mucosal immunity. Nat Med 8 (2002) 567-573
36. Neurath M.F., Fuss I., Kelsall B.L., Stuber E., and Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182 (1995) 1281-1290
37. Nochi T., and Kiyono H. Innate immunity in the mucosal immune system. Curr Pharm Des 12 (2006) 4203-4213
38. Patel M., Xu D., Kewin P., Choo-Kang B., McSharry C., Thomson N.C., et al. TLR2 agonist ameliorates established allergic airway inflammation by promoting Th1 response and not via regulatory T cells. J Immunol 174 (2005) 7558-7563
39. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 347 (2002) 417-429
40. Powrie F., Correa-Oliveira R., Mauze S., and Coffman R.L. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 179 (1994) 589-600
41. Re F., and Strominger J.L. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 276 (2001) 37692-37699
42. Rosignoli F., Torroba M., Juarranz Y., Garcia-Gomez M., Martinez C., Gomariz R.P., et al. VIP and tolerance induction in autoimmunity. Ann N Y Acad Sci 1070 (2006) 525-530
43. Said S.I., and Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 169 (1970) 1217-1218
44. Shanahan F. Crohn's disease. Lancet 359 (2002) 62-69
45. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359 (1992) 693-699
46. Takeuchi O., and Akira S. Toll-like receptors; their physiological role and signal transduction system. Int Immunopharmacol 1 (2001) 625-635
47. Underhill D.M., and Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 14 (2002) 103-110
48. Viglietta V., Baecher-Allan C., Weiner H.L., and Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199 (2004) 971-979
49. Xu D., Komai-Koma M., and Liew F.Y. Expression and function of Toll-like receptor on T cells. Cell Immunol 233 (2005) 85-89
50. Zipris D., Lien E., Xie J.X., Greiner D.L., Mordes J.P., and Rossini A.A. TLR activation synergizes with Kilham rat virus infection to induce diabetes in BBDR rats. J Immunol 174 (2005) 131-142